医学
危险系数
指南
肾病
肾功能
内科学
置信区间
对数秩检验
风险因素
肾脏疾病
胃肠病学
比例危险模型
病理
糖尿病
内分泌学
作者
Bingxin Yu,Sufang Shi,Jicheng Lv,Lijun Liu,Shufeng Zhou,Li Zhu,Pei Chen,Hongyu Yang,Zi Wang,Suxia Wang,Jonathan Barratt,Hong Zhang
摘要
Rapidly progressive immunoglobulin A nephropathy (RPIgAN) is a severe clinical phenotype of IgAN associated with a poor outcome. The recently published Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Guideline for the Management of Glomerular Diseases has proposed a new definition for RPIgAN that is based simply on a ≥50% decline in the estimated glomerular filtration rate (eGFR) over ≤3 months.In 1677 IgAN patients followed at a single centre in China, we evaluated the utility of this new definition to identify the highest-risk IgAN patients who might be suitable for combination immunosuppressive therapy.The proportion of a ≥50% decline in eGFR over ≤3 months was 5.2%. The majority of these patients had reversible causes, with only 2.3% (39/1677) meeting the KDIGO 2021 criteria for RPIgAN. These patients had a significantly higher risk for end-stage kidney disease (ESKD) than non-RPIgAN patients (logrank P < 0.001). RPIgAN was an independent risk factor for ESKD [hazard ratio 3.99 (95% confidence interval 2.25-7.09); P <0.001]. A minority of the RPIgAN patients (25.6%) had ≥50% crescents. There was no significant difference in the risk for ESKD between patients in the RPIgAN group with ≥50% crescents and ˂50% crescents (logrank P = 0.27). Patients with RPIgAN and ≥50% crescents had a higher risk for ESKD than patients with non-RPIgAN and ≥50% crescents (logrank P = 0.04).These data support the validity of the KDIGO 2021 definition but require independent validation in other non-Chinese cohorts.
科研通智能强力驱动
Strongly Powered by AbleSci AI